(United States, Nevada, Las Vegas), DelveInsight’s“Botulism – Pipeline Insight, 2023” report provides comprehensive insights about 4+ companies and 5+ pipeline drugs in the Botulism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Over 4+ companies and 5+ pipeline drugs in Botulism are in various stages of development, and their anticipated acceptance in the Botulism market would significantly increase market revenue.
Leading Botulism companies developing novel drug candidates to improve the Botulism treatment landscape include XOMA, CytoDel, AlphaVax, PanThera Biopharma, and others
Promising Botulism pipeline therapies in various stages of development include Biodefence vaccines, NTM-1633, and many others.
Botulism is a rare, naturally occurring disease that is caused by botulinum toxins from bacteria called Clostridium botulinum. It is transmitted through food, contact with contaminated soil, or through an open wound. The symptoms of Botulism include constipation, drooping eyelids, paralysis, difficulty swallowing or speaking, facial weakness on both sides of the face, blurred vision, trouble breathing, nausea, vomiting, and abdominal cramps (only in foodborne botulism). A diagnosis of Botulism is made based on a thorough physical examination, a detailed patient history, and a variety of specialized tests. The standard test is a brain scan, cerebrospinal fluid examination, electromyography, and/or edrophonium chloride test for myasthenia gravis. Early diagnosis of foodborne or wound botulism can be cured with antitoxin. The antitoxin attaches itself to a toxin that’s still circulating in the bloodstream. In infants, a treatment known as botulism immune globulin blocks the actions of neurotoxins circulating in the blood. If the infection results from a wound, the wound needs to be treated surgically.
Botulism Pipeline Analysis: Drug Profile
Biodefence vaccines: AlphaVax
AlphaVax is developing immunostimulants as biodefence vaccines using Alphavaccine Platform System. The system is genetically derived from a modified alphavirus. The re-engineered alpha vaccine particles express the substituted gene (or genes), rather than producing more virus particles, thereby transforming the original virus into a highly effective vaccine system. Alphavaccines is currently in preclinical development for the treatment of botulism.
Discover more about the emerging Botulism drugs @ Botulism Treatment Drugs
Botulism Pipeline Therapies and Key Companies
Biodefence vaccines: AlphaVax
And many others
Botulism Pipeline Therapeutics Assessment
DelveInsight’s Report covers around 5+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Botulism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Scope of the Botulism Pipeline Report
Key Botulism Companies: XOMA, CytoDel, AlphaVax, PanThera Biopharma, and others
Key Botulism Pipeline Therapies: Biodefence vaccines, NTM-1633, and others.
Find out more about the Botulism treatment options in development @ Botulism Clinical Trials
Table of Contents
1. Botulism Introduction
2. Botulism Executive Summary
3. Botulism Overview
4. Botulism Pipeline Therapeutics
5. Botulism Late-Stage Products (Phase III)
6. Botulism Mid-Stage Products (Phase II)
7. Botulism Early Stage Products (Phase I/II)
8. Botulism Preclinical Stage Products
9. Botulism Discovery Stage Products
10. Botulism Therapeutic Assessment
11. Botulism Inactive Products
12. Botulism Collaborations Assessment- Licensing / Partnering / Funding
13. Botulism Unmet Needs
14. BotulismMarket Drivers and Barriers
16. About DelveInsight
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States